160 related articles for article (PubMed ID: 35117834)
1.
Hou H; Jia D; Yan W; Zhang X; Wang C; Li Y; Chen H; Huang W; Li Z; Zhang X
Transl Cancer Res; 2020 Aug; 9(8):4703-4714. PubMed ID: 35117834
[TBL] [Abstract][Full Text] [Related]
2. The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.
Disel U; Madison R; Abhishek K; Chung JH; Trabucco SE; Matos AO; Frampton GM; Albacker LA; Reddy V; Karadurmus N; Benson A; Webster J; Paydas S; Cabanillas R; Nangia C; Ozturk MA; Millis SZ; Pal SK; Wilky B; Sokol ES; Gay LM; Soman S; Ganesan S; Janeway K; Stephens PJ; Zhu VW; Ou SI; Lovly CM; Gounder M; Schrock AB; Ross JS; Miller VA; Klempner SJ; Ali SM
Oncologist; 2020 Jan; 25(1):e39-e47. PubMed ID: 31604903
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies.
Ross JS; Wang K; Rand JV; Sheehan CE; Jennings TA; Al-Rohil RN; Otto GA; Curran JC; Palmer G; Downing SR; Yelensky R; Lipson D; Balasubramanian S; Garcia L; Mahoney K; Ali SM; Miller VA; Stephens PJ
Am J Surg Pathol; 2014 Feb; 38(2):235-8. PubMed ID: 24418857
[TBL] [Abstract][Full Text] [Related]
4. Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study.
Nobusawa S; Stawski R; Kim YH; Nakazato Y; Ohgaki H
Neuropathology; 2011 Dec; 31(6):583-8. PubMed ID: 21382095
[TBL] [Abstract][Full Text] [Related]
5. Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma.
Thierauf J; Ramamurthy N; Jo VY; Robinson H; Frazier RP; Gonzalez J; Pacula M; Dominguez Meneses E; Nose V; Nardi V; Dias-Santagata D; Le LP; Lin DT; Faquin WC; Wirth LJ; Hess J; Iafrate AJ; Lennerz JK
Oncologist; 2019 Oct; 24(10):1356-1367. PubMed ID: 30926674
[TBL] [Abstract][Full Text] [Related]
6. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
[TBL] [Abstract][Full Text] [Related]
7. PDGFRA, KIT, and KDR Gene Amplification in Glioblastoma: Heterogeneity and Clinical Significance.
Carlotto BS; Trevisan P; Provenzi VO; Soares FP; Rosa RFM; Varella-Garcia M; Zen PRG
Neuromolecular Med; 2023 Sep; 25(3):441-450. PubMed ID: 37610648
[TBL] [Abstract][Full Text] [Related]
8. The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer.
Jansson S; Bendahl PO; Grabau DA; Falck AK; Fernö M; Aaltonen K; Rydén L
PLoS One; 2014; 9(7):e102176. PubMed ID: 25025175
[TBL] [Abstract][Full Text] [Related]
9. Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma.
Burford A; Little SE; Jury A; Popov S; Laxton R; Doey L; Al-Sarraj S; Jürgensmeier JM; Jones C
PLoS One; 2013; 8(8):e71777. PubMed ID: 23990986
[TBL] [Abstract][Full Text] [Related]
10. Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors.
Blom T; Roselli A; Häyry V; Tynninen O; Wartiovaara K; Korja M; Nordfors K; Haapasalo H; Nupponen NN
J Neurooncol; 2010 Apr; 97(2):217-24. PubMed ID: 19779861
[TBL] [Abstract][Full Text] [Related]
11. The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment.
Zietsch J; Ziegenhagen N; Heppner FL; Reuss D; von Deimling A; Holtkamp N
PLoS One; 2010 Jul; 5(7):e11858. PubMed ID: 20686603
[TBL] [Abstract][Full Text] [Related]
12. Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations.
Suehara Y; Alex D; Bowman A; Middha S; Zehir A; Chakravarty D; Wang L; Jour G; Nafa K; Hayashi T; Jungbluth AA; Frosina D; Slotkin E; Shukla N; Meyers P; Healey JH; Hameed M; Ladanyi M
Clin Cancer Res; 2019 Nov; 25(21):6346-6356. PubMed ID: 31175097
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.
Chau NG; Hotte SJ; Chen EX; Chin SF; Turner S; Wang L; Siu LL
Ann Oncol; 2012 Jun; 23(6):1562-70. PubMed ID: 22080184
[TBL] [Abstract][Full Text] [Related]
15. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas.
Puputti M; Tynninen O; Sihto H; Blom T; Mäenpää H; Isola J; Paetau A; Joensuu H; Nupponen NN
Mol Cancer Res; 2006 Dec; 4(12):927-34. PubMed ID: 17189383
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.
Ho AL; Dunn L; Sherman EJ; Fury MG; Baxi SS; Chandramohan R; Dogan S; Morris LG; Cullen GD; Haque S; Sima CS; Ni A; Antonescu CR; Katabi N; Pfister DG
Ann Oncol; 2016 Oct; 27(10):1902-8. PubMed ID: 27566443
[TBL] [Abstract][Full Text] [Related]
17. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.
Holtkamp N; Okuducu AF; Mucha J; Afanasieva A; Hartmann C; Atallah I; Estevez-Schwarz L; Mawrin C; Friedrich RE; Mautner VF; von Deimling A
Carcinogenesis; 2006 Mar; 27(3):664-71. PubMed ID: 16357008
[TBL] [Abstract][Full Text] [Related]
18. Predictive and prognostic value of phosphorylated c-KIT and PDGFRA in advanced non-small cell lung cancer harboring ALK fusion.
Yang H; Wang F; Deng Q; Xiao D; He P; Lin X; He D
Oncol Lett; 2019 Mar; 17(3):3071-3076. PubMed ID: 30867736
[TBL] [Abstract][Full Text] [Related]
19. Differential KIT expression in histological subtypes of adenoid cystic carcinoma (ACC) of the salivary gland.
Freier K; Flechtenmacher C; Walch A; Devens F; Mühling J; Lichter P; Joos S; Hofele C
Oral Oncol; 2005 Oct; 41(9):934-9. PubMed ID: 16054424
[TBL] [Abstract][Full Text] [Related]
20. C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma.
Penner CR; Folpe AL; Budnick SD
Mod Pathol; 2002 Jul; 15(7):687-91. PubMed ID: 12118104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
